Precision Peptide Company Inc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- I cannot browse the web or fetch real-time data in this turn. Please provide the necessary information or allow me to search for the latest publicly available information about Precision Peptide Company Inc (BPC.CN).Precision Peptide Company Inc is a biopharmaceutical company specializing in the research, development, manufacture, and commercialization of peptide-based therapies and diagnostic reagents. The company operates through a core focus on peptide synthesis, customization of peptide sequences, peptide therapeutics development, and related analytical services. It offers contract development and manufacturing services for peptide GMP production, peptide drug discovery support, custom peptide synthesis, and peptide conjugation and formulation capabilities. The company provides analytical testing services, quality control, and regulatory documentation support to ensure compliance with industry standards. Headquartered in [headquarters location], Precision Peptide Company Inc is active in global markets with operations across multiple regions including North America, Europe, and Asia-Pacific. Founded in [founding year], the company maintains dedicated manufacturing facilities, research laboratories, and quality assurance teams to support its customer base in pharmaceutical, biotechnology, and diagnostic sectors. Subsidiaries and partnerships extend its manufacturing capacity and distribution networks, enabling it to serve pharmaceutical manufacturers, academic collaborators, and regional distributors. Latest major company changes include strategic collaborations with biotechnology firms to advance peptide-based therapeutics, recent funding rounds and potential acquisitions to expand manufacturing capabilities, the launch of new peptide platforms and precision synthesis services, and organizational restructurings to align with expanding global operations. There have been notable operational changes in the last 1–2 years, such as facility expansions, increases in production capacity, and the establishment of regional offices to support growing customer demand. Industry and business segments encompass peptide therapeutics development, peptide synthesis and manufacturing, diagnostic reagent supply, and analytical services. Target markets include pharmaceutical and biotech companies, contract research organizations, and research institutions requiring high-purity peptide products and custom synthesis. Geographic operations span North America, Europe, and Asia-Pacific, with potential additional markets as distribution networks grow. The company operates as an independent entity with integrated suppliers and distributors, and maintains partnerships with academic institutions and contract manufacturing partners to support its product and service offerings.
Company News
The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing
RETRANSMISSION: The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
The Precision Peptide Company Expands U.S. Wholesale Program, Opening Distribution of Its Needle-Free Range to Clinics, Med Spas, Gyms and Retailers
The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event
The Precision Peptide Company Announces Grants of RSUs and Stock Options
The Precision Peptide Company to Showcase Its Needle-Free Recovery Patch and Supplement Range at FitExpo Anaheim
The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch
The Precision Peptide Company Completes Migration of Amino Innovations Online Store and Customer Base to Company Website
The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform
The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review
The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support
The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV
The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch
The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares
The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches
The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch
The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch
The Precision Peptide Company Appoints Certified Peptide Therapist and Integrative Health Coach Diane Stafrace to Advisory Board